stockportfolio.pro
Standard BioTools Inc. (LAB)
Healthcare · Medical Devices · NasdaqGS
Standard BioTools Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.45M | $101.94M | $112.96M | $117.24M | $138.14M | $130.58M | $97.95M | $106.34M | $91.01M | $85.33M |
| Gross profit | $58.44M | $51.98M | $61.65M | $64.28M | — | — | $37.05M | $50.45M | $44.88M | $42.54M |
| Net income | $-75.98M | $-60.53M | $-59.01M | $-64.79M | $-53.02M | $-59.24M | $-190.10M | $-74.66M | $-138.88M | $-74.90M |
| Net margin | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% |
Source: Standard BioTools Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Standard BioTools Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LAB in your portfolio →
Standard BioTools Inc. financial history by metric
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Standard BioTools Inc. — frequently asked questions
What is Standard BioTools Inc.'s revenue?
Standard BioTools Inc. (LAB) reported revenue of $85.33M for fiscal year 2025, down 6.2% from the prior year, according to its SEC filings.
Is Standard BioTools Inc. profitable?
No — LAB reported a net loss of $-74.90M in fiscal 2025.
What is LAB's P/E ratio?
Standard BioTools Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Standard BioTools Inc. growing?
LAB's revenue grew at roughly -9.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Standard BioTools Inc. have?
As of fiscal year 2025, LAB carried roughly $299,000 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Standard BioTools Inc.'s gross margin?
LAB's gross margin was 49.9% in fiscal 2025 — gross profit of $42.54M on revenue of $85.33M.
What is Standard BioTools Inc.'s market cap?
Standard BioTools Inc. (LAB) has a market capitalization of about $346.01M, based on the latest data in our nightly-refreshed cache.
When does Standard BioTools Inc.'s fiscal year end?
LAB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Standard BioTools Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.